Emcure Pharma: Why These 3 Global Partnerships Could Make Namita Thapar’s Stock A Watchlist Candidate 

Synopsis: Shark Tank India judge Namita Thapar’s Emcure Pharma has been signing partnerships with global pharma companies like Novo Nordisk, Sanofi and Roche while expanding into newer therapies. But are these deals simply adding products, or could they shape the company’s next phase of growth and make it a stock to watch? 

India’s pharmaceutical market is changing. Investors are no longer only looking at companies that sell basic medicines at scale. The bigger interest is now moving towards companies that can sell specialised medicines, work with global innovators, build strong doctor relationships and still grow profitably. This is where partnerships are becoming important because many global drug companies want strong local partners instead of building everything on their own.

Shark Tank India judge Namita Thapar’s Emcure Pharma is one such company that is trying to use this strategy. The company has already crossed the USD 1 billion revenue milestone, with FY26 revenue growth of 16.6 percent, base business EBITDA margin expansion of over 100 basis points and adjusted PAT growth of more than 40 percent. Management said FY26 was the first year of its five-year strategy, focused on turning earlier operational changes into measurable results.

But the more interesting story is not just the FY26 result. It is the company’s growing list of global partnerships. During the year, Emcure highlighted three important tie-ups: Novo Nordisk for Poviztra, Sanofi for oral anti-diabetic brands and Roche for nephrology and transplant medicines. These deals show that Emcure is trying to move deeper into high-value therapies rather than depend only on its existing domestic portfolio.

What Does Emcure Actually Do?

Emcure is a pharma company with both India and international businesses. Its India business is focused on therapy areas such as gynaecology, cardiac, diabetology, oncology, CNS, nephrology, anti-infectives, vitamins, dermatology and consumer wellness. 

Emcure has 11 brand families with revenue above Rs. 100 crore, 32 brand families above Rs. 50 crore, and 19 of its top 20 brands ranked among the top three in their respective therapy areas. It is also ranked number 2 in gynaecology domestically.

The international side is also large. Emcure sells in 70-plus countries and has exposure to Europe, Canada and Rest of World markets. International complex products contribute around 30 percent of international revenue, while domestic complex products contribute around 50 percent of domestic revenue. This matters because complex products are usually less commoditised than plain generics.

In simple terms, Emcure is not trying to be just a volume-led medicine company. It is trying to become a stronger specialty pharma player, where branded products, complex injectables, biosimilars, in-licensed products and international launches all work together.

Why The Novo Nordisk Partnership Matters

The first and most attention-grabbing partnership is with Novo Nordisk. Emcure was selected as the exclusive India partner for Poviztra, a patented rDNA biologic semaglutide. Management made it clear that this product is different from synthetic-origin products in the market and said Poviztra has strong global data and an established device. It also said initial uptake has been promising after the April 2026 price cut, and the company is aiming for steady growth through FY27.

This is important because semaglutide is linked to obesity and weight management, which is a fast-growing area. In the Q2FY26 call, management said India has around 25 crore obese or overweight people, and the Novo partnership gives Emcure early entry into the obesity market compared with competition.

For Emcure, this deal does two things. First, it gives the company access to a high-interest therapy area without spending years developing the product itself. Second, it strengthens Emcure’s position in metabolic therapies, which is already becoming a focus area for the company. BOBCAPS also noted that Poviztra is expected to scale with marketing by 1,000 dedicated medical representatives, which shows that Emcure is not treating this as a small side product.

Sanofi And Roche Add Depth To The India Business

The second major partnership is with Sanofi. Emcure expanded its Sanofi partnership to include the oral anti-diabetic brands Amaryl and Cetapin. Management said this boosts Emcure’s position in cardiac and metabolic therapies and gives it a stronger foothold in the metabolic space.

This matters because these are established brands, not experimental launches. In Q1FY26, management said Emcure would market and distribute Sanofi’s oral diabetic portfolio, including Amaryl and Cetapin, from August 2025. It also said the Sanofi cardiovascular portfolio, along with metabolics, is helping Emcure emerge as a stronger cardio-diabeto player.

The third partnership is with Roche. Emcure signed a distribution agreement for select nephrology and transplant medicines in India, with billing starting from April 1. Management said Emcure is already one of the top five companies in nephrology, and the Roche portfolio will help strengthen its position further.

This is not a huge revenue contributor today. BOBCAPS mentioned that the Roche portfolio is small, with two to three brands and annualised revenue below Rs. 50 crore, with no upfront payment. But strategically, it takes Emcure deeper into specialty therapies where doctor relationships and credibility matter more.

Why These Partnerships Are Important For Growth

The real point is not that Emcure has three big-name partners. The bigger point is that in-licensing is already becoming a meaningful part of the company’s India business. BOBCAPS said Emcure’s in-licensed portfolio contributes around 15 percent of domestic sales and is likely to grow, supported by Poviztra, Roche and Sanofi brands. That makes the partnerships financially relevant. They are not just for reputation. They are already part of the domestic revenue engine.

The second reason is that these products improve the quality of the portfolio. Novo adds semaglutide and obesity exposure. Sanofi strengthens diabetes and metabolic therapies. Roche adds nephrology and transplant medicines. Together, these deals push Emcure towards higher-value therapies.

The third reason is that Emcure already has a commercial engine to scale these products. The company has large brands, therapy leadership and strong doctor reach. The company mentioned that India business is being strengthened with new areas, in-licensing and leadership.

This is why global companies may find Emcure useful. A company like Novo or Roche does not only need a distributor. It needs a partner that can take specialised medicines to doctors, hospitals and patients in the right therapy areas.

The International Business Is Also Doing Heavy Lifting

While the main story is about partnerships, investors cannot ignore the international business. In FY26, Emcure’s revenue grew to Rs. 9,204 crore, EBITDA was Rs. 1,789 crore, and adjusted PAT was Rs. 1,008 crore. The company said FY26 revenue growth was led by robust performance in international markets, while EBITDA margin improved to 19.4 percent due to productivity enhancement and scaling of in-house products.

In Q4FY26, revenue from operations grew 16.7 percent to Rs. 2,470 crore. Domestic business grew only 5.2 percent to Rs. 977 crore, but international revenue grew 25.7 percent to Rs. 1,493 crore. Europe grew 35.8 percent, Canada grew 28.6 percent, and Emerging Markets grew 15.5 percent.

This is important because it gives Emcure more than one growth engine. If India has a soft quarter, international markets can still support overall growth. BOBCAPS expects the international business to grow at a 15 percent CAGR over FY26-FY29, helped by Amphotericin B penetration in Europe and Rest of World, Manx in Europe, Marcan in Canada, semaglutide partnership with Dr. Reddy’s in Quebec and ARV orders.

What Could Go Wrong?

The biggest near-term issue is the domestic slowdown caused by Zuventus. In Q4FY26, management said the domestic business was softer because of the Zuventus portfolio and team reorganisation, which caused higher attrition. It said integration and new leadership hires have addressed the issue and April was tracking according to plan.

BOBCAPS also mentioned that around Rs. 80-90 crore of business was lost in Q4 due to Zuventus, and that around 40 percent of Emcure’s field force is in Zuventus. It also said attrition was well above the normal 20-30 percent range due to management change and portfolio restructuring.

So the issue does not look structural yet, but it needs watching. If India growth normalises in FY27, then investors may treat Q4 as a temporary disruption. But if the drag continues, it can weaken the domestic growth story.

The second risk is that in-licensed products can be slightly dilutive at the gross margin level. Management said such deals may be lower on gross margin, but should be healthier at EBITDA, ROCE and cash flow levels because they usually require little or no upfront payment.

The third risk is execution. Partnerships only matter if Emcure can scale products profitably. Poviztra, Roche, Sanofi and international launches all need proper doctor engagement, pricing, supply and field-force execution.

Still, the reason Emcure becomes a stock to watch is simple. The company is not depending on one trigger. It has domestic brands, global partnerships, international growth, complex injectables, biosimilars and a specialty pipeline. FY26 already showed that the model can deliver revenue growth and margin improvement. Now the key question is whether these partnerships can make the next phase of growth stronger, broader and more profitable.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Emcure Pharma: Why These 3 Global Partnerships Could Make Namita Thapar’s Stock A Watchlist Candidate  appeared first on Trade Brains.